Medindia LOGIN REGISTER
Medindia
Advertisement

Vanda Wins Appeal Case on Fanapt®

Friday, April 13, 2018 General News
Advertisement
U.S. Court of Appeals Affirms District Court's Decision

WASHINGTON, April 13, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delaware's decision that West Ward Pharmaceuticals, a subsidiary of Hikma Pharmaceuticals, infringed Vanda's U.S. Patent number 8,586,610 (the '610 Patent) for Fanapt®.  The '610 Patent is set to expire November 2, 2027. 
Advertisement

About Vanda Pharmaceuticals Inc.

Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.  For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.
Advertisement

About Fanapt®

For full U.S. Prescribing Information for Fanapt®, including indication, Boxed Warnings and Important Safety Information, visit our Web site at www.fanapt.com.

Investor Contact: Jim Kelly Executive Vice President & Chief Financial Officer Vanda Pharmaceuticals Inc. (202) 734-3428 [email protected]

Cision View original content:http://www.prnewswire.com/news-releases/vanda-wins-appeal-case-on-fanapt-300629612.html

SOURCE Vanda Pharmaceuticals Inc.

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close